

HEADQUARTERS

31 Ifigenias, 2007 Nicosia, Cyprus • P.O.Box 28807, 2083 Nicosia, Cyprus
Tel.: +357 22 319 129, Fax: +357 22 314 552, E-mail: thalassaemia@cytanet.com.cy

THALASSAEMIA
INTERNATIONAL
FEDERATION



OFFICIAL GLOBAL PRESS RELEASE

The TIF International Conference on Thalassaemia and Haemoglobinopathies returns on 3-5 November in Kuala Lumpur



NICOSIA [October 30, 2023] — The Thalassaemia International Federation announces the return of its much-anticipated **International Conference on Thalassaemia and Other Haemoglobinopathies (TIF2023)**. This prestigious event ranks among the leading international conferences in the field, bringing together physicians, academics, policy makers, and patients to share the latest scientific data and address topical concerns.

The Conference will take place from **3 to 5 November 2023, in Kuala Lumpur, Malaysia**. Boasting over 60 eminent speakers from across the globe, the three-day programme features a wide array of specialized talks and thematic sessions focused on enhancing knowledge and understanding of these conditions.

Aiming to inform, educate and provide a platform for constructive dialogue and exchange of knowledge and experience on thalassaemia, sickle cell disease and rare anaemias, the Conference will consist of two parallel programmes - a scientific programme for physicians and health professionals and a programme specifically designed for patients, parents, and caregivers of people with thalassaemia.

The scientific programme's key highlights include lectures and presentations by renowned experts from countries such as Cyprus, Greece, the US, the UK, Italy, Australia, the UAE, and Lebanon. Topics include addressing health inequalities and unmet patient needs, diagnosis and care of α -thalassaemia, cutting-edge research on haemoglobinopathies treatment, gene therapy advancements, and more.

Particular emphasis will be placed on the education and empowerment of patients, whose active participation and contribution in the management of their disease is of paramount importance at all levels of decision-making, both at national and regional level. At the same time, the conference will serve as a "forum" for the exchange of experiences among attendees, through interactive sessions and experiential lectures by people with thalassaemia and haemoglobinopathies from a multitude of countries.

Various satellite events will also take place to highlight the latest innovations in scientific research on thalassaemia and sickle cell disease.

"We are excited to announce the return of our International Conference on Thalassaemia and Haemoglobinopathies, a highly regarded event in the field. This comes at a critical juncture marked by significant scientific advances, updated health policies, and evolving challenges in the therapeutic management of these diseases," stated **Dr. Androulla Eleftheriou, Executive Director of TIF**. *"Our three-day event aims to offer an essential platform for researchers, scientists, healthcare professionals, and patients to exchange knowledge, inspire one another, and contribute to improving care for millions affected by thalassaemia worldwide."*

The conference will feature internationally renowned personalities and leaders of influential health organizations, including **Dr. Tedros Andhanom Ghebreyesus**, Director-General of the World Health Organization; **Dr. Stella Kyriakidou**, European Commissioner for Health and Food Safety; and **Dr. Zaliha Mustafa**, Malaysian Minister of Health.

The keynote lecture will be presented by esteemed Professor Zilfalil bin Alwi, UNESCO Chair in Human Genetics of Thalassaemia, on *"The importance of thalassaemia to the global genome project."*

During the conference, updated and new editions of TIF's internationally acclaimed educational materials will be distributed to participants. Conclusions drawn from the proceedings will guide recommendations for national health authorities, enabling them to devise focused policies for the ideal prevention and management of thalassaemia and haemoglobinopathies.

TIF2023 is organized under the auspices of the Malaysian Ministry of Health and supported by the Malaysian Society of Haematology, the Malaysian Association of Pediatric Haematology and Oncology, and the Federation of Malaysia Thalassaemia Societies.

Global industry leaders in haematology research and development, including Bristol Myers Squibb, Agios Pharmaceuticals, and Vertex Pharmaceuticals, are sponsoring the event

For more information on the TIF International Conference on Thalassaemia and Haemoglobinopathies, please visit the official conference website: <https://tif2023.org/>